Literatur zum Titelthema „Neu in der Urologie“

von Professor Dr. Thomas Horn, Dr. Matthias Jahnen, Dr. Philipp Korn, Dr. Kira Schüller
Professorin Dr. Margitta Retz und Professor Dr. Jürgen E. Gschwend

Bayerisches Ärzteblatt 7-8/2024, Seite 304 ff.

1. Culp, M.B., et al., *Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.* Eur Urol, 2020. **77**(1): p. 38-52.
2. Kelly, S.P., et al., *Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.* Eur Urol Focus, 2018. **4**(1): p. 121-127.
3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF), S3-Leitlinie Prostatakarzinom, Langversion 7.01, 2024, AWMF- Registernummer: 043-022OL 2024.
4. Krilaviciute, A., et al., *Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer.* Eur Urol Oncol, 2023. **6**(6): p. 566-573.
5. Frånlund, M., et al., *Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial.* J Urol, 2022. **208**(2): p. 292-300.
6. Hugosson, J., et al., *A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.* Eur Urol, 2019. **76**(1): p. 43-51.
7. Moore, C.M. and P. Albertsen, *When Is It Too Early To Start Prostate Cancer Screening? Reflections on the PROBASE Study Using Magnetic Resonance Imaging for Men Aged 45 Yr with Elevated Prostate-specific Antigen.* Eur Urol, 2024. **85**(2): p. 112-113.
8. Auvinen, A., et al., *Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.* Jama, 2024.
9. Hugosson, J., et al., *Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.* N Engl J Med, 2022. **387**(23): p. 2126-2137.
10. Kasivisvanathan, V., et al., *MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.* N Engl J Med, 2018. **378**(19): p. 1767-1777.
11. Rouvière, O., et al., *Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.* Lancet Oncol, 2019. **20**(1): p. 100-109.
12. Turkbey, B., et al., *Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.* Eur Urol, 2019. **76**(3): p. 340-351.
13. *EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023.*
14. Asif, A., et al., *Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol.* BMJ Open, 2023. **13**(4): p. e070280.
15. Jahnen, M., et al., *Does experience change the role of systematic biopsy during MRI-fusion biopsy of the prostate?* World J Urol, 2023. **41**(10): p. 2699-2705.
16. Hu, J.C., et al., *Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial.* European Urology, 2024.
17. Berry, B., et al., *Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study.* BJU Int, 2020. **126**(1): p. 97-103.
18. Toussi, A., et al., *Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?* J Urol, 2016. **195**(6): p. 1754-9.
19. Perera, M., et al., *Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.* Eur Urol, 2020. **77**(4): p. 403-417.

20. Freedland, S.J., et al., *Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.* N Engl J Med, 2023. **389**(16): p. 1453-1465.
21. Ost, P., et al., *Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.* Eur Urol, 2015. **67**(5): p. 852-63.
22. Phillips, R., et al., *Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.* JAMA Oncol, 2020. **6**(5): p. 650-659.
23. Knipper, S., et al., *Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.* Eur Urol, 2023. **83**(1): p. 62-69.
24. Steuber, T., et al., *Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.* Eur Urol Focus, 2019. **5**(6): p. 1007-1013.
25. Bravi, C.A., et al., *Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.* Eur Urol, 2020. **78**(5): p. 661-669.
26. Lunger, L., et al., *Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases.* Eur Urol Oncol, 2023. **6**(1): p. 95-98.
27. Galsky, M.D., et al., *Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.* J Clin Oncol, 2011. **29**(17): p. 2432-8.
28. Kim, Y.R., et al., *Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma.* Cancer Chemother Pharmacol, 2015. **76**(1): p. 141-53.
29. Bajorin, D.F., et al., *Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.* N Engl J Med, 2021. **384**(22): p. 2102-2114.
30. Klaassen, Z. *EAU 2024: Extended Follow-up from CheckMate 274 Including the First Report of Overall Survival Outcomes*. 2024 23.04.2024].
31. Stecca, C., O. Abdeljalil, and S.S. Sridhar, *Metastatic Urothelial Cancer: a rapidly changing treatment landscape.* Ther Adv Med Oncol, 2021. **13**: p. 17588359211047352.
32. Sternberg, C.N., et al., *M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.* J Urol, 1988. **139**(3): p. 461-9.
33. von der Maase, H., et al., *Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.* J Clin Oncol, 2000. **18**(17): p. 3068-77.
34. Powles, T., et al., *Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.* J Clin Oncol, 2023. **41**(19): p. 3486-3492.
35. Powles, T., et al., *Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.* N Engl J Med, 2024. **390**(10): p. 875-888.
36. Powles, T., et al., *Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.* N Engl J Med, 2021. **384**(12): p. 1125-1135.